SavedAdd your journal

Journals / Hacettepe Journal of Biology and Chemistry / 2020 / Cilt: 48 - Sayı: 3

Disulfide-rich peptides in drug development

Şeyda KARA
Muharrem AKCAN
Pages
219–229
Publication Date
2020-06-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review describes the structure and bioactivity of disulfide-rich peptides and their development with various modifications to become candidate molecules in drug design and development studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Peptides are important biomolecules in drug development with their high specificities to their targets.
📊
Key Findings & Data:Many peptide-based drug candidates have been increasingly involved in clinical and preclinical studies.
💡
Conclusion & Impact:This review describes the structure and bioactivity of disulfide-rich peptides and their development with various modifications to become candidate molecules in drug design and development studies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Therapeutic peptides · drug development · cyclotides

Abstract

Peptides are important biomolecules in drug development with their high specificities to their targets. Many peptide-based drug candidates have been increasingly involved in clinical and preclinical studies. Unfortunately, peptides have some disadvantages such as poor metabolic stability, poor oral bioavailability and high production costs. These problems can be overcome by modifications that have been inspired from highly stable disulfide-rich peptides already found in nature. This review describes the structure and bioactivity of disulfide-rich peptides and their development with various modifications to become candidate molecules in drug design and development studies.

🔖

Cite This Article

KARA, Ş., AKCAN, M. (2020). Disulfide-rich peptides in drug development. Hacettepe Journal of Biology and Chemistry, Cilt: 48 - Sayı: 3, 219–229. https://ajindex.com/articles/255685

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. P. Chames, M. Van Regenmortel, E. Weiss, D. Baty, Therapeutic antibodies: successes, limitations and hopes for the future, Br J Pharmacol, 157 (2009) 220-233
  2. N. Munoz-Durango, M. S. Pizarro-Ortega, E. Rey-Jurado, F. E. Diaz, S. M. Bueno, A. M. Kalergis, Patterns of antibody response during natural hRSV infection: insights for the development of new antibody-based therapies. Expert Opin Investig Drugs, 27 (2018) 721-731
  3. T. M. Pierpont, C. B. Limper, K. L. Richards, Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol, 8 (2018) 163
  4. J. L. Lau, M. K. Dunn, Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem, (2017) 2700-2707
  5. R. Koradi, M. Billeter, K. Wuthrich, MOLMOL: A program for display and analysis of macromolecular structures. Journal of Molecular Graphics, 14(1996) 51-55
  6. L. Thorstholm, D. J. Craik, Discovery and applications of naturally occurring cyclic peptides. Drug Discov Today Technol, 9 (2012) e1-e70
  7. J. Koehbach, D. J. Craik, The Vast Structural Diversity of Antimicrobial Peptides, Trends in Pharmacological Sciences, 40 (2019) 517-528
  8. J. F. Borel, C. Feurer, H. U. Gubler, H. Stahelin, Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions, 6 (1976) 468-475
  9. C. Spitzfaden, H. P. Weber, W. Braun, J. Kallen, G. Wider, H. Widmer, M. D. Walkinshaw, K. Wuthrich, Cyclosporin A-cyclophilin complex formation. A model based on X-ray and NMR data. FEBS Lett, 300 (1992) 291-300
  10. X. Yang, P. Feng, Y. Yin, K. Bushley, J W. Spatafora, C. Wang, Cyclosporine Biosynthesis in Tolypocladium inflatum Benefits Fungal Adaptation to the Environment. mBio, 9 (2018) e01211-01218
  11. J. Klages, C. Neubauer, M. Coles, H. Kessler, B. Luy, Structure refinement of cyclosporin a in chloroform by using RDCs measured in a stretched PDMS-gel. Chembiochem, 6 (2005) 1672-1678
  12. J. C. O'Shea, J. E. Tcheng, Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. Expert Opin Pharmacother, 3 (2002) 1199-1210
  13. D. W. Cushman, M. A. Ondetti, History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 17(1991) 589-592
  14. A. Lodha, M. Kamaluddeen, A. Akierman, H. Amin, Role of hemocoagulase in pulmonary hemorrhage in preterm infants: a systematic review. Indian J. Pediatrics, 78 (2011) 838-844
  15. S. J. Ho, T. A. Brighton, Xime